clinical trial · NCT07900516
A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.
The First Affiliated Hospital with Nanjing Medical University·phase2·recruiting·n = 48
Breast CancerKumoxiliDocetaxelEpirubicinCyclophosphamideLetrozoleEverolimus (Afinitor®)
brief summary
To explore the efficacy and safety of Culmerciclib combined with chemotherapy as neoadjuvant therapy for HR+/HER2- breast cancer patients who are insensitive to neoadjuvant TAC (docetaxel, doxorubicin, cyclophosphamide) chemotherapy.
started
Aug 1, 2026
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Oct 28, 2026
official title
A Prospective, Phase II, Exploratory Study Evaluating Neoadjuvant Therapy With a Culmerciclib -Containing Combination Regimen in Patients With HR-Positive, HER2-Negative Breast Cancer Who Are Insensitive to Neoadjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) Chemotherapy.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol